产品
编 号：F561998
分子式：C18H25NO3S
分子量：335.46
分子式：C18H25NO3S
分子量：335.46
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 188532-26-5
产品详情
生物活性：
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.
体内研究：
NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; daily; for 5 days
Result:Showed antileukemic activity in an in vivo mouse ALL model.
体外研究：
NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.
体内研究：
NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; daily; for 5 days
Result:Showed antileukemic activity in an in vivo mouse ALL model.
体外研究：
NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备